Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
renal cell carcinoma
Pharma
BMS' Opdivo, Aveo's Fotivda fail as combo in kidney cancer
Despite failure as part of a combination with Opdivo, Aveo is touting the performance of Fotivda as a monotherapy in kidney cancer.
Kevin Dunleavy
Jul 18, 2024 4:26pm
FDA signs off on 2nd approval for Merck's Welireg
Dec 15, 2023 11:33am
Merck looks to broaden Welireg's reach in kidney cancer
Aug 18, 2023 11:12am
Lonza signs on with Allarity to produce cancer drug candidate
Sep 23, 2021 3:23pm
BMS's Opdivo-Yervoy flunks test in squamous head and neck cancer
Jul 16, 2021 11:26am
Ipsen steps in to help Exelixis' Cabometyx in thyroid cancer
May 12, 2021 11:08am
